Abstract:Enhancing therapeutic activity against cancer cells and minimizing toxic effects on normal cells are critical elements in chemotherapy. In this issue of Cancer Cell, Leite de Oliveira and colleagues reveal a previously unrecognized role of a prolyl hydroxylase domain in promoting drug delivery to tumors and reducing toxicity in normal organs. Enhancing therapeutic activity against cancer cells and minimizing toxic effects on normal cells are critical elements in chemotherapy. In this issue of Cancer Cell, Leite de Oliveira and colleagues reveal a previously unrecognized role of a prolyl hydroxylase domain in promoting drug delivery to tumors and reducing toxicity in normal organs. Chemotherapy using cytotoxic agents, such as doxorubicin and cisplatin, to damage cancer cells and inhibit tumor growth remains a major therapeutic modality in cancer treatment. The low selectivity of cytotoxic agents in killing cancer cells over normal cells has been a major challenge and significantly limits the application of these drugs for cancer treatment. This problem is further compounded by the fact that tumors usually have blood vessels that seem to be leaky and tend to cause high interstitial fluid pressure. This abnormal vasculature limits drug delivery to cancer cells and, therefore, reduces the effectiveness of systemic chemotherapy (Carmeliet and Jain, 2011Carmeliet P. Jain R.K. Nat. Rev. Drug Discov. 2011; 10: 417-427Crossref PubMed Scopus (1182) Google Scholar; Heldin et al., 2004Heldin C.H. Rubin K. Pietras K. Ostman A. Nat. Rev. Cancer. 2004; 4: 806-813Crossref PubMed Scopus (1593) Google Scholar). In most cases, the administration of higher drug doses to increase drug concentrations in tumor tissues is not a practical option due to the risk of severe side effects. Although local administration by injecting cytotoxic agents into the tumor or the main blood vessels feeding the tumor may enhance anticancer activity and reduce systemic toxicity, such approaches may only be applied to a small subset of tumors at certain anatomic locations. Clearly, new therapeutic approaches, including novel strategies to normalize the aberrant tumor vessels and developing tumor-specific agents, are needed to improve cancer treatment outcome. Recent studies suggest that targeting the prolyl hydroxylase domain-containing protein 2 (PHD2) may lead to normalization of blood vessels in tumors (Mazzone et al., 2009Mazzone M. Dettori D. Leite de Oliveira R. Loges S. Schmidt T. Jonckx B. Tian Y.M. Lanahan A.A. Pollard P. Ruiz de Almodovar C. et al.Cell. 2009; 136: 839-851Abstract Full Text Full Text PDF PubMed Scopus (630) Google Scholar) and prevent oxygen-induced microvascular obliteration in the retina (Duan et al., 2011Duan L.J. Takeda K. Fong G.H. Am. J. Pathol. 2011; 178: 1881-1890Abstract Full Text Full Text PDF Scopus (29) Google Scholar) through HIF-dependent mechanisms. Prolyl hydroxylases are a family of enzymes that catalyze the hydroxylation of proline residues in a variety of proteins and affect multiple biological functions including collagen formation, oxygen sensing, RNA transcription, and NF-κB signaling (Gorres and Raines, 2010Gorres K.L. Raines R.T. Crit. Rev. Biochem. Mol. Biol. 2010; 45: 106-124Crossref PubMed Scopus (406) Google Scholar). Among the prolyl hydroxylases, PHD2 seems to play a major role in oxygen sensing and blood vessel formation and significantly affects cancer oxygenation and metastasis. It was recently shown that heterozygous deletion of Phd2 in mice caused an increased expression of HIF-1α and HIF-2α in endothelial cells, leading to the transition of endothelial tip cells to a more quiescent stage and normalization of the endothelial lining of tumor vasculatures (Mazzone et al., 2009Mazzone M. Dettori D. Leite de Oliveira R. Loges S. Schmidt T. Jonckx B. Tian Y.M. Lanahan A.A. Pollard P. Ruiz de Almodovar C. et al.Cell. 2009; 136: 839-851Abstract Full Text Full Text PDF PubMed Scopus (630) Google Scholar). The profound effect of PHD2 on the structure of tumor blood vessel provides the intriguing possibility of targeting this molecule to normalize blood flow in tumor tissues and to increase drug delivery to cancer cells. In this issue of Cancer Cell, Leite de Oliveira et al., 2012Leite de Oliveira R. Deschoemaeker S. Henze A.-T. Debackere K. Finisguerra V. Takeda Y. Roncal C. Detorri D. Tack E. Jönsson Y. et al.Cancer Cell. 2012; 22 (this issue): 263-277Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar report that reduced PHD2 expression by heterozygous gene deletion could significantly enhance the therapeutic activity of doxorubicin and cisplatin in mice and substantially reduce the toxic side effects of the drugs in normal organs, such as the heart and kidneys. These striking effects seem to be mediated by two separate mechanisms, both linked to the activation of hypoxia inducible factors (Figure 1). First, the decrease in PHD2 activity caused a significant increase in HIF-1α and HIF-2α protein levels in endothelial cells, leading to a normalization of the endothelial lining of blood vessels within tumor tissues. This, in turn, improved blood circulation and reduced interstitial fluid pressure in the tumor, resulting in an increase in the delivery of anticancer agents to the tumor. The authors suggest that this mechanism was mainly mediated through the oxygen-sensing function of PDH2 via HIF-2. In contrast, the blood circulation in normal organs seemed not to be affected by heterozygous deletion of Phd2, and there was no increase in drug concentrations in the normal tissues. Importantly, Phd2 deficiency in normal cells led to HIF-mediated upregulation of several key antioxidant enzymes, including superoxide dismutases, catalase, and glutathione peroxidase-1, which enhanced the antioxidant capacity of normal cells and increased their ability to tolerate the production of reactive oxygen species (ROS) induced by anticancer drugs. The authors showed that the protection of normal organs by Phd2 heterozygous deletion was likely due to activation of the ROS-sensing mechanism of HIF-1 and HIF-2, which upregulate the expression of antioxidant enzymes. The significant in vivo antitumor activity of doxorubicin and cisplatin observed in Phd2+/− mice suggests that targeting PDH2 is a potentially promising strategy to improve the overall therapeutic outcome for cancer patients and that the local drug concentrations in tumor tissues may play a major role in determining in vivo drug response. However, other mechanisms, in addition to increased local drug concentrations, could contribute to the striking inhibition of tumor growth by doxorubicin and cisplatin in Phd2+/− mice. For instance, Phd2 deletion might, through the activation of HIF-1 and HIF-2, affect the energy metabolism and redox regulation in tumor stroma and, thus, potentially impair stromal support for the tumor cells. Indeed, recent studies suggest that the tumor-stromal cell interaction plays a major role in affecting the ROS status in cancer cells and their drug sensitivity (Zhang et al., 2012Zhang W. Trachootham D. Liu J. Chen G. Pelicano H. Garcia-Prieto C. Lu W. Burger J.A. Croce C.M. Plunkett W. et al.Nat. Cell Biol. 2012; 14: 276-286Crossref PubMed Scopus (241) Google Scholar; Nakasone et al., 2012Nakasone E.S. Askautrud H.A. Kees T. Park J.H. Plaks V. Ewald A.J. Fein M. Rasch M.G. Tan Y.X. Qiu J. et al.Cancer Cell. 2012; 21: 488-503Abstract Full Text Full Text PDF PubMed Scopus (360) Google Scholar). Thus, testing the potential role of PHD2 in modulating tumor-stroma interaction would be an interesting area of future investigation. It is important to note that the normalization of tumor blood vasculature in Phd2+/− mice seem to be mediated, at least in part, by the HIF-driven upregulation of VEGFR1 and VE-cadherin (Mazzone et al., 2009Mazzone M. Dettori D. Leite de Oliveira R. Loges S. Schmidt T. Jonckx B. Tian Y.M. Lanahan A.A. Pollard P. Ruiz de Almodovar C. et al.Cell. 2009; 136: 839-851Abstract Full Text Full Text PDF PubMed Scopus (630) Google Scholar). Thus, suppression of the VEGF pathway might potentially have an opposite and perhaps unfavorable effect. Indeed, inhibition of angiogenesis by blocking VEGF using the humanized monoclonal antibody bevacizumab has been shown to cause a decrease in the delivery of anticancer drugs to the tumor tissues (Van der Veldt et al., 2012Van der Veldt A.A. Lubberink M. Bahce I. Walraven M. de Boer M.P. Greuter H.N. Hendrikse N.H. Eriksson J. Windhorst A.D. Postmus P.E. et al.Cancer Cell. 2012; 21: 82-91Abstract Full Text Full Text PDF Scopus (263) Google Scholar). These observations together suggest that caution should be exercised in considering combination of VEGF blocking drugs and traditional chemotherapeutic agents. The proper timing of drug administration would be important in avoiding potential antagonist effect. The two major consequences of Phd2 deletion, namely normalization of tumor vasculature and enhancement of antioxidant and detoxification capacity in normal organs, suggest that pharmacological inhibition of PHD2 may be an effective strategy to increase the therapeutic activity and reduce the toxic side-effect of traditional chemotherapeutic agents. However, systemic administration of PHD2 inhibitors might potentially cause an increase in HIF-1 and HIF-2 in cancer cells and, in turn, upregulation of detoxification enzymes and drug resistance. However, the observation by Leite de Oliveira et al., 2012Leite de Oliveira R. Deschoemaeker S. Henze A.-T. Debackere K. Finisguerra V. Takeda Y. Roncal C. Detorri D. Tack E. Jönsson Y. et al.Cancer Cell. 2012; 22 (this issue): 263-277Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar that silencing of Phd2 in tumor cells did not significantly alter their expression of antioxidant enzymes and drug response seem to ease this potential concern, although the mechanisms responsible for the major difference between normal cells and cancer cells in their response to PHD2 abrogation remain largely unclear. This is obviously an important area for future study. Furthermore, since there are multiple prolyl hydroxylases that affect many important biological functions, development of specific inhibitors of PHD2 is important for successful pharmacological targeting. In summary, the study by Leite de Oliveira et al., 2012Leite de Oliveira R. Deschoemaeker S. Henze A.-T. Debackere K. Finisguerra V. Takeda Y. Roncal C. Detorri D. Tack E. Jönsson Y. et al.Cancer Cell. 2012; 22 (this issue): 263-277Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar suggests that PHD2 is a promising therapeutic target and warrants further in vitro and in vivo studies in terms of mechanisms and clinical applications. Gene-Targeting of Phd2 Improves Tumor Response to Chemotherapy and Prevents Side-ToxicityLeite de Oliveira et al.Cancer CellAugust 14, 2012In BriefThe success of chemotherapy in cancer treatment is limited by scarce drug delivery to the tumor and severe side-toxicity. Prolyl hydroxylase domain protein 2 (PHD2) is an oxygen/redox-sensitive enzyme that induces cellular adaptations to stress conditions. Reduced activity of PHD2 in endothelial cells normalizes tumor vessels and enhances perfusion. Here, we show that tumor vessel normalization by genetic inactivation of Phd2 increases the delivery of chemotherapeutics to the tumor and, hence, their antitumor and antimetastatic effect, regardless of combined inhibition of Phd2 in cancer cells. Full-Text PDF Open Archive

Abstract 378: PHD3 dependent stabilization of β3-adrenoceptor induces HIF-1αactivation in Ewing sarcoma

Abstract P4-08-23: ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer

Abstract 1787: The β3-adrenergic receptor as novel target of metabolic phenotype in Ewing sarcoma

Prolyl Hydroxylase Domain 3 Influences the Radiotherapy Efficacy of Pancreatic Cancer Cells by Targeting Hypoxia-Inducible Factor-1Α

Abstract B7: Activation of PPARα Suppresses HIF-1α Signaling in Human Cancer Cells.

Abstract 711: HDAC3 sustains resistance to hypofractionated radiotherapy in fusion positve rhabdomyosarcoma cells

HIF-1 transcription activity: HIF1A driven response in normoxia and in hypoxia

HIF-1α links β-adrenoceptor agonists and pancreatic cancer cells under normoxic condition

Abstract 119: Stabilization of Hypoxia-Inducible Factor-1Α by the Human Rhomboid Family-1 Gene Product RHBDF1

Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis

Abstract 5271: Pseudohypoxia by HIF-PHD inhibitors activates tumor immune response for MSS colorectal cancer

Abstract 4812: Inhibition of Smurf2 E3 ubiquitin ligase by heclin and its analogues enhances HIF-1α expression and transcriptional activity in normoxia or hypoxia

A New Role for PHD in Chemotherapy

Abstract 379: Landscape of HIF-1α expression across 24,186 solid tumors using comprehensive immune profiling

Abstract 1638: Hypoxia-induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells

Hypoxia Alters the Response to Anti-EGFR Therapy by Regulating EGFR Expression and Downstream Signaling in a DNA Methylation-Specific and HIF-Dependent Manner

Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia‐inducible factor 1α

Abstract 87: EHD1 is required for IGF1R-mediated oncogenic signaling in Ewing Sarcoma

Abstract PR12: Targeting Eif2α Phosphorylation for Cancer Therapy

Abstract A048 SR59230A-induced ferroptosis sensitization of Ewing sarcoma cells via Beta-3 adrenergic receptor modulation: A novel therapeutic target

Abstract #4216: A Role for C-Src in EGFR-induced Upregulation of HIF-1\#945;